8-K
filed June 22, 2023, 7:59 PM ET
ticker IRWD
CIK 0001446847
other material
confidence high
sentiment neutral
materiality 0.30
Ironwood shareholders approve new equity plan and director slate at 2023 annual meeting
IRONWOOD PHARMACEUTICALS INC
- All nine director nominees elected, including Mark Currie, Alexander Denner, Andrew Dreyfus, Jon Duane, Marla Kessler, Thomas McCourt, Julie McHugh, Catherine Moukheibir, Jay Shepard.
- Non-binding advisory vote on executive compensation approved: 124,448,271 for, 2,240,534 against, 261,827 abstain.
- Stockholders recommended future say-on-pay votes every year (121,938,287 for 1-year; broker non-votes 8,009,329).
- Amended and Restated 2019 Equity Incentive Plan approved: 119,042,503 for, 7,783,479 against; adds up to 16,000,000 new shares plus prior plan forfeitures.
- Ratification of Ernst & Young as auditor for 2023: 131,145,295 for, 3,631,560 against, 183,106 abstain.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
IRONWOOD PHARMACEUTICALS INC shareholders approved Advisory vote on frequency of future say-on-pay votes (every year) at the 2023-06-20 meeting.
- Proposal
- say on pay frequency
- Outcome
- passed
- Meeting
- 2023-06-20
Exact text from the filing
The stockholders recommended, on a non-binding advisory basis, that future non-binding advisory votes to approve the compensation of the Company’s named executive officers, be held once every year, based on the following votes:
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
IRONWOOD PHARMACEUTICALS INC shareholders approved Advisory vote to approve named executive officer compensation at the 2023-06-20 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-06-20
Exact text from the filing
The stockholders approved, on a non-binding advisory basis, the compensation paid to the Company’s named executive officers, as disclosed in the Company’s proxy statement for the Annual Meeting, based on the following votes:
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
IRONWOOD PHARMACEUTICALS INC shareholders approved Approval of Amended and Restated 2019 Equity Incentive Plan at the 2023-06-20 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-06-20
Exact text from the filing
The stockholders approved the Company’s Plan, based on the following votes:
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
IRONWOOD PHARMACEUTICALS INC shareholders approved Ratification of Ernst & Young LLP as independent auditor for 2023 at the 2023-06-20 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-20
Exact text from the filing
The stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2023, based on the following votes:
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
IRONWOOD PHARMACEUTICALS INC shareholders approved Election of nine directors at the 2023-06-20 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-20
Exact text from the filing
The stockholders elected nine director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2024 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based on the following votes:
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.